Why does the V1613M variant reduce amyloid pathology when ABCA7 loss-of-function increases AD risk?

Analysis ID: SDA-2026-04-14-gap-pubmed-20260410-180532-e8930cb8 | Domain: neurodegeneration | Status: failed | Created: 2026-04-14T04:26:48.693793

Knowledge Graph: 1 edges — View JSON

Top Hypotheses (2 total)

#1 CSF Biomarker-Guided ABCA7 Therapeutic Dosing

0.619

ABCA7 with biomarker-guided dosing

## CSF Biomarker-Guided ABCA7 Therapeutic Dosing in Neurodegeneration ### The ABCA7 Gene and Lipid Homeostasis ABCA7 (ATP-binding cassette transporter A7) is a critical regulator of lipid homeostasi

#2 ABCA7-TREM2 Co-Targeting for Microglial Lipid Handling

0.538

ABCA7 + TREM2 (combinatorial)

# ABCA7-TREM2 Co-Targeting for Microglial Lipid Handling ## Mechanistic Foundation The convergence of ABCA7 and TREM2 signaling on microglial lipid metabolism represents a compelling therapeutic axi

← Back to all analyses